Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ORKA 
Oruka Therapeutics, Inc. (ORKA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: ORKA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $49.45
1 Year Target Price $49.45
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 205.54% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.53B USD | Price to earnings Ratio - | 1Y Target Price 49.45 |
Price to earnings Ratio - | 1Y Target Price 49.45 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 5.49 - 32.64 | Updated Date 12/29/2025 |
52 Weeks Range 5.49 - 32.64 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1190260654 | Price to Sales(TTM) - |
Enterprise Value 1190260654 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 48409232 | Shares Floating 31574922 |
Shares Outstanding 48409232 | Shares Floating 31574922 | ||
Percent Insiders 2.95 | Percent Institutions 95.27 |
Upturn AI SWOT
Oruka Therapeutics, Inc.
Company Overview
History and Background
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases and cancer. Founded in 2017, the company has advanced its lead asset, ORK-001, into clinical trials. Oruka's evolution is marked by strategic partnerships and a commitment to leveraging its proprietary technology platform to address unmet medical needs.
Core Business Areas
- Autoimmune Diseases: Focuses on developing novel therapies for a range of autoimmune conditions, utilizing its understanding of immune system modulation.
- Oncology: Explores the potential of its therapeutic candidates in treating various forms of cancer, aiming to improve patient outcomes.
Leadership and Structure
Oruka Therapeutics, Inc. is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The organizational structure is lean and agile, prioritizing scientific innovation and efficient clinical development.
Top Products and Market Share
Key Offerings
- Competitors: Pfizer (Xeljanz), AbbVie (Humira), Bristol Myers Squibb (Orencia), and various other biopharmaceutical companies in the autoimmune space.
- Description: A novel therapeutic candidate currently in clinical development for autoimmune diseases. Specific market share data for early-stage clinical assets is not publicly available. Competitors include established pharmaceutical companies with approved therapies for autoimmune conditions and other biotechs in similar stages of development.
- Market Share Data:
- Product Name 1: ORK-001
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the autoimmune and oncology sectors, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. It is driven by innovation, unmet medical needs, and the pursuit of more effective and safer treatments.
Positioning
Oruka Therapeutics, Inc. is positioned as an emerging player in the biopharmaceutical landscape, focusing on innovative approaches to treat complex diseases. Its competitive advantage lies in its proprietary technology and a pipeline of novel drug candidates targeting specific immunological pathways.
Total Addressable Market (TAM)
The TAM for autoimmune disease treatments and oncology is substantial, running into hundreds of billions of dollars globally. Oruka Therapeutics, Inc. aims to capture a portion of this market by developing differentiated therapies for specific patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced management team
- Focus on high-unmet-need areas
- Promising early-stage clinical data
Weaknesses
- Clinical-stage company with no approved products
- Reliance on external funding
- Limited manufacturing capacity
- Early stage of clinical development for lead asset
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in personalized medicine
- Growing demand for innovative autoimmune and cancer treatments
Threats
- Clinical trial failures
- Regulatory challenges and delays
- Competition from established players and emerging biotechs
- Changes in healthcare policy and reimbursement
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
- Pfizer Inc. (PFE)
- Gilead Sciences, Inc. (GILD)
Competitive Landscape
Oruka Therapeutics, Inc. faces intense competition from large, established pharmaceutical companies with significant resources and approved products. Its competitive advantage relies on developing truly novel and differentiated therapies that offer superior efficacy or safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Oruka Therapeutics, Inc. has experienced growth in its R&D efforts and advancement of its pipeline since its inception. This growth is primarily measured by progress in preclinical and clinical studies.
Future Projections: Future projections are contingent on successful clinical trial outcomes, regulatory approvals, and market adoption. Analyst coverage for such early-stage companies is limited and projections are highly uncertain.
Recent Initiatives: Key recent initiatives would include the progression of ORK-001 into clinical trials, potential new research collaborations, and securing necessary funding for ongoing development.
Summary
Oruka Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company with a focus on innovative therapies for autoimmune diseases and cancer. Its strengths lie in its proprietary technology and experienced team. However, as an early-stage company, it faces significant risks related to clinical development, funding, and regulatory approvals. Success hinges on the successful progression of its pipeline and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry analysis reports
- Financial news outlets
- Biopharmaceutical industry databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in clinical-stage biotechnology companies involves substantial risk, and investors should conduct their own due diligence before making any investment decisions. Market share data for early-stage companies is often estimated or based on broad therapeutic areas.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://orukatx.com |
Full time employees 28 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.